, Tracking Stock Market Picks
Enter Symbol:
Valeant Pharmaceuticals International Inc (VRX) [hlAlert]

up 246.13 %

Valeant Pharmaceuticals International Inc (VRX) rated Buy with price target $180 by Aegis Capital

Posted on: Thursday,  Feb 27, 2014  10:25 AM ET by Aegis Capital

Aegis Capital rated Buy Valeant Pharmaceuticals International Inc (NYSE: VRX) on 02/27/2014. Previously Aegis Capital rated Buy Valeant Pharmaceuticals International Inc (NYSE: VRX)
on 02/22/2013., when the stock price was $65.65. Since then, Valeant Pharmaceuticals International Inc has gained 246.14% as of 01/06/2016's recent price of $227.24.
If you would have followed the previous Aegis Capital's recommendation on VRX, you would have gained 246.13% of your investment in 1048 days.

Valeant Pharmaceuticals International is a multi-national specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. The Company focuses on the therapeutic areas of dermatology and neurology. Its products are sold through three segments: Specialty Pharmaceuticals, Branded Generics (Europe) and Branded Generics (Latin America). In January 2008, the Company sold its product rights to Three Rivers Pharmaceuticals, LLC. In June 2008, the Company sold its subsidiaries in Argentina and Uruguay. In September 2008, the Company sold its business operations located in Western and Eastern Europe, Middle East and Africa (the WEEMEA business) to Meda AB of Sweden. In October 2008, the Company completed a worldwide License and Collaboration Agreement with Glaxo Group Limited, a wholly owned subsidiary of GlaxoSmithKline plc. In May 2009, the Company acquired EMO-FARM Ltd., a privately held company located in Poland.

Aegis Capital
as of 1/1/0001
1 Week   
1 Month   
3 Months   
1 YTD   

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy